Provided by Tiger Trade Technology Pte. Ltd.

SKB BIO

528.500
0.000
Volume:303.90K
Turnover:160.36M
Market Cap:126.31B
PE:-274.23
High:537.500
Open:519.000
Low:519.000
Close:528.500
52wk High:581.000
52wk Low:339.600
Shares:239.00M
HK Float Shares:177.00M
Volume Ratio:0.51
T/O Rate:0.17%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-1.927
ROE:-9.34%
ROA:-5.11%
PB:22.31
PE(LYR):-274.23
PS:52.77

Loading ...

Movement Alert|SKB BIO Rises 3.15% in Regular Trading, Dual-Payload ADC Drug SKB565 Approved for Clinical Trials Ahead of Interim Results Review

Market Focus
·
Aug 07

Is Sichuan Kelun Biotech Biopharmaceutical (SEHK:6990) Cheap As ADC Pipeline News Builds?

Simply Wall St.
·
Aug 06

Global AI Competition Heats Up, Commodity Stocks Rally in Hong Kong Markets

Stock News
·
Aug 06

Hong Kong Stock Moves: SKB BIO Surges Over 4% Before Noon as New Dual-Load ADC Drug Gets Clinical Trial Approval

Stock News
·
Aug 06

Movement Alert|SKB BIO Rises 3.4% in Regular Trading, Interim Results Review Approaching Amid Pipeline Catalysts

Market Focus
·
Aug 06

SKB BIO Sets 17 Aug 2026 Board Meeting to Approve 1H26 Interim Results; Announces Same-Day Webcast

Bulletin Express
·
Aug 05

Kelun-Biotech Schedules Webcast Conference Call on Interim Results

Reuters
·
Aug 05

SKB BIO commits RMB 400.00 million to third BOC structured deposit, lifting total holdings to RMB 1.10 billion

Bulletin Express
·
Aug 04

SKB BIO Invests 400 Million Yuan in Bank of China Structured Deposits

Stock News
·
Aug 04

Sichuan Kelun-Biotech Biopharmaceutical Subscribes to BOC Structured Deposit III for Rmb400 MLN

Reuters
·
Aug 04

Sichuan Kelun-Biotech Biopharmaceutical Co - Subscribes to BOC Structured Deposit Iii for Rmb400 Mln on August 4, 2026

THOMSON REUTERS
·
Aug 04

Movement Alert|SKB BIO Declines 3.35% in Regular Trading, Commercial Bribery Allegations Continue to Weigh on Shares as Strict New Pharma Regulations Take Effect

Market Focus
·
Aug 03

Sichuan Kelun Biotech (SEHK:6990) Wins Priority Review For Sixth Sac TMT Indication

Simply Wall St.
·
Aug 01

Movement Alert|SKB BIO Rises 3.78% in Regular Trading, Core TROP2 ADC New Indication Application Accepted by NMPA

Market Focus
·
Jul 31

SKB Biopharma's New Indication Application for Breast Cancer Drug Candidate Accepted in China

MT Newswires Live
·
Jul 30

Kelun-Biotech (SKB BIO): NMPA Accepts Sixth Indication Filing for TROP2 ADC sac-TMT as First-Line Therapy in PD-L1-Low TNBC

Bulletin Express
·
Jul 30

Kelun-Biotech Says China Regulator Accepts sac-TMT Filing for First-line Metastatic TNBC Use

Reuters
·
Jul 30

Sichuan Kelun-Biotech Biopharmaceutical Co - Nmpa Accepts New Indication Application for Sac-TMT in First-Line Tnbc

THOMSON REUTERS
·
Jul 30

Movement Alert|SKB BIO Declines 3.01% in Regular Trading, Trading at 482.6 HKD

Market Focus
·
Jul 30

MerckRapidly Advances ADC+IO 2.0 Strategy with SKB BIO's TROP2 ADC Joint PD-1/VEGF Bispecific Antibody Phase II Trial

Deep News
·
Jul 29